Analysts feel R&D costs are set to rise as a result of injectables and biosimilars focus
from Latest News http://bit.ly/2Q1DpRG
Thursday, 27 December 2018
Aurobindo's injectable business grows 8% year-on-year to $50 mn in Q2
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment